Bristol-myers Squibb Compnay

Rose C Christian

Dasa Lipovsek

Ray Camphausen

Paul E Morin

Daniel Cohen

Ranjan Mukherjee

Timothy Patrick Reilly

John Krupinski

Edgar Davidson Charles, Iii

Yi Luo

Nucleic acids encoding modified FGF-21 polypeptides, optionally containing at least one non-codon encoding a naturally-encoded amino acid, and vectors and cells containing are provided. These nucleic acids can be used to express the modified FGF-21 polypeptide encoded thereby. The expressed FGF-21 polypeptides may be used as therapeutics, e.g., in the treatment of diseases associated with fibrosis.

Nucleic acids encoding modified FGF-21 polypeptides, vectors and cells containing, and use thereof

Provided herein are methods for treating a patient having NASH who has been determined to have a particular threshold level of serum Pro-C3 (e.g., greater than 10 ng/ML) by administering to the patient a modified Fibroblast growth factor 21 (FGF-21) in an amount and with a frequency sufficient to treat NASH. Also provided are methods for monitoring responsiveness of a patient having NASH to treatment with a modified FGF-21, the method comprising: determining the serum Pro-C3 level in a blood sample from the patient obtained during or after treatment, wherein: a decreased serum Pro-C3 level in the blood sample from the patient obtained during or after treatment, as compared to the serum Pro-C3 level in a blood sample from the patient obtained prior to treatment with the modified FGF-21, indicates that the patient is responsive to treatment with the modified FGF-21.

Modified fibroblast growth factor 21 (FGF-21) for use in methods for treating nonalcoholic steatohepatitis (NASH)

Modified FGF-21 polypeptides and uses thereof are provided, for example, for the treatment of diseases associated with fibrosis. Modified FGF-21 polypeptides are disclosed that contain an internal deletion and optionally replacement peptide, optionally modified with at least one non-naturally-encoded amino acid, and/or optionally fused to a fusion partner.

Methods of treating diseases associated with fibrosis using modified FGF-21 polypeptides

Methods of treating diseases associated with fibrosis using modified FGF-21 polypeptides and uses thereof

Therapeutic uses of modified FGF-21 polypeptides

Modified FGF-21 polypeptides comprising an internal deletion and uses thereof

Growing community of inventors

Lawrenceville, NJ, United States of America

Rose C Christian